Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 2 4Phase 1/2 4Phase NA 2Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Breast Neoplasms 3856Neoplasms 2988Prostatic Neoplasms 1751Colorectal Neoplasms 1426Lung Neoplasms 1328Motor Activity 802Head and Neck Neoplasms 683Pancreatic Neoplasms 663Colonic Neoplasms 655Uterine Cervical Neoplasms 648Carcinoma, Non-Small-Cell Lung 629Carcinoma, Hepatocellular 628Rectal Neoplasms 569Stomach Neoplasms 544Brain Neoplasms 483Ovarian Neoplasms 438Anxiety Disorders 419Pain 418Neoplasm Metastasis 385Esophageal Neoplasms 384Polycystic Ovary Syndrome 374Precursor Cell Lymphoblastic Leukemia-Lymphoma 354Urinary Bladder Neoplasms 351Fatigue 339Melanoma 322Multiple Myeloma 321Lymphoma 305Depression 305Endometrial Neoplasms 289Liver Neoplasms 279

Interventions

Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase NA × Neoplasms, Nerve Tissue × Clear all
NCT04446416 2026-04-09

Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients

NaviFUS Corporation

Phase NA Completed
6 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue

NCT03626896 2019-06-21

Safety of BBB Disruption Using NaviFUS System in Recurrent Glioblastoma Multiforme (GBM) Patients

NaviFUS Corporation

Phase NA Completed
6 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue

Data powered by HemOnc (CC BY 4.0) Colophon âš¡